Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
Study Details
Study Description
Brief Summary
Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
To determine treatment and patient reported outcomes, following cataract surgery with intraocular lens implant in conjunction with minimally invasive glaucoma surgery (MIGS) more specifically iStent, iStent inject or KDB with an intracanalicular dexamethasone (0.4 mg) insert, inserted four days (+/- 1 day) prior to surgery as compared to insertion on day of surgery. Patients with either primary open angle glaucoma (POAG) or ocular hypertension (OHTN) requiring cataract surgery with IOL implant, will be separated into two groups.
Group 1: intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery) Group 2: intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Insertion visit 4 days prior Intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery) |
Drug: Intracanalicular Dexamethasone, 0.4 mg insert
Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
Other Names:
|
| Other: Surgical 1 visit day 0 Intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery) |
Drug: Intracanalicular Dexamethasone, 0.4 mg insert
Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery or inserted the day of surgery.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Intracanalicular Dexamethasone, 0.4 mg insert four days (+/- 1 day) prior to surgery [four days (+/- 1 day) prior to surgery with visits scheduled at day 1, day 7, day 14, day 30, and day 45.]
Primary: Will receive the insert four days (+/- 1 day) prior to surgery. Each enrolled subject will be required to complete seven scheduled visits over the course of the study period: Baseline, insertion visit, operative visit, Day 1, 7, 30, and a 14 & 45-day phone call. Absence of cells in anterior chamber at day 7 as measured by: Summed Ocular Inflammation Score (0-4) Absence of cell to be defined as a grade of (0-0.5) Absence of pain at Day 7 (score of 0) as measured by ocular pain assessment numerical grading scale 0-10 Mean change in BCVA from baseline (Day 7,30) Mean change in OCT from baseline (Day 30) Physician ease of intracanalicular insertion evaluation as measured by physician questionnaire Incidence and severity of ocular and systemic AE's (Day 1,7,14,30,45)
Secondary Outcome Measures
- Intracanalicular Dexamethasone, 0.4 mg insertion on day of surgery. [insertion on day of surgery with scheduled visits on day 1, day 7, day 14, day 30, and day 45.]
Secondary: Will receive the insert on the day of surgery. Each enrolled study subject will be required to complete six scheduled visits over the course of the study period: Screening visit, operative/insertion visit, Day 1, 7, 30, and a 14 & 45 day phone call. Measuring cell, pain and flare at (Day 1,30) Absence of cell to be defined as a grade of (0-0.5) Absence of flare to be defined as a grade of (0-1) Determining if call backs have decreased at the clinic with study patients
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18 years and older
-
Been diagnosed with POAG or OHTN and MIGS (iStent, iStent inject or KDB) has been planned
-
Unilateral or bilateral cataract surgery with IOL has been planned
-
Willing and able to comply with clinic visits and study related procedures
-
Willing and able to sign the informed consent form
Exclusion Criteria:
-
Patients under the age of 18.
-
Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
-
Active infectious systemic disease
-
Active infectious ocular or extraocular disease
-
Unobstructed nasolacrimal duct in the study eye(s)
-
Hypersensitivity to dexamethasone
-
Patients being treated with immunomodulating agents in the study eye(s)
-
History of prior ocular surgery, including Lasik or PRK
-
History of ocular inflammation or macular edema
-
Patients being treated with >375mg daily of NSAIDs
o Patients on doses higher than 375mg of oral NSAIDs will be considered if they discontinue the medication 2 weeks prior to the study start date.
-
Patients taking inconsistent varying doses of an NSAID on a daily basis.
-
Patients being treated with immunosuppressants and/or oral steroids
-
Patients with a corticosteroid implant (i.e. Ozurdex)
-
Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Wolstan and Goldberg Eye Associates | Torrance | California | United States | 90505 |
Sponsors and Collaborators
- Wolstan and Goldberg Eye Associates
Investigators
- Principal Investigator: Damien Goldberg, MD, Wolstan & Goldberg Eye Associates
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DEXTENZA